Ipilimumab: A novel treatment for metastatic melanoma;Ipilimumab: Un nuevo tratamiento para el melanoma metastásico

Annals of Pharmacotherapy

Volumn 45, Issue 4, 2011, Pages 510-519

  Culver, Morgan E ^a   Gatesman, Mandy L ^b   Mancl, Erin E ^b   Lowe, Denise K ^b  

^a NOTRE DAME OF MARYLAND UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Ipilimumab; MDX 010; MDX 101; Metastatic melanoma

Indexed keywords

CARBOPLATIN; DACARBAZINE; DOCETAXEL; GLYCOPROTEIN GP 100; INTERLEUKIN 2; IPILIMUMAB; PACLITAXEL; TEMOZOLOMIDE; UNCLASSIFIED DRUG; YERVOY;

ABDOMINAL PAIN; ADRENAL INSUFFICIENCY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CHILL; COLITIS; CONSTIPATION; CORTICOTROPIN BLOOD LEVEL; COUGHING; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEADACHE; HEMATOCHEZIA; HUMAN; HYPOPHYSITIS; HYPOPITUITARISM; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; SURVIVAL RATE; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MELANOMA; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN NEOPLASMS; UNITED STATES;

EID: 79955579231     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P651     Document Type: Article

References (55)

1. National Cancer Institute. Melanoma. http://www.cancer.gov/cancertopics/types/melanoma (accessed 2010 Aug 12).
2. American Cancer Society. Melanoma skin cancer. http://www.cancer.org/Cancer/SkinCancer-Melanoma/DetailedGuide/index (accessed 2010 Aug 12).
3. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206.
4. National Cancer Institute. Surveillance epidemiology and end results. Melanoma. http://seer.cancer.gov/statfacts/htm (accessed 2010 Aug 10).
5. Cascinelli N, Bufalino R, Marolda R et al. Regional non-nodal metastases of cutaneous melanoma. Eur J Surg Oncol 1986;12:175-80.
6. Kretschmer L, Beckmann I, Thoms KM, Mitteldorf C, Bertsch HP, Neumann C. Factors predicting the risk of in-transit recurrence after sentinel lymphonodectomy in patients with cutaneous malignant melanoma. Ann Surg Oncol 2006;13:1105-12.
7. McCarthy WH, Shaw HM, Thompson JF, Milton GW. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study. Surg Gynecol Obstet 1988;166:497-502.
8. Roses DF, Harris MN, Rigel D, Carrey Z, Friedman R, Kopf AW. Local and in-transit metastases following definitive excision for primary cutaneous malignant melanoma. Ann Surg 1983;198:65-9.
9. National Comprehensive Cancer Network. The NCCN Melanoma Clinical Practice Guidelines in Oncology (V 2.2010). http://www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf (accessed 2010 Aug 15).
10. Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004;22: 2101-7.
11. Smith FO, Downey SG, Klapper JA, et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008;14:5610-18.
12. Zimpfer-Rechner C, Hofmann U, Figl R, et al. Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as secondline therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res 2003; 13:531-6.
13. Chan Y, Papadopoulos NE, Camacho LH, et al. The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma. Melanoma Res 2010;20:43-7.
14. Hayes E. Yervoy cuts to the head of the line: Ipilimumab has unrestricted label. The Pink Sheet. March 28, 2011.
15. Bristol-Myers Squibb. Ipilimumab receives FDA priority review designation for adult patients with previously treated advanced melanoma. http://www.bms.com/news/press_releases/pages/default.aspx (accessed 2010 Aug 19).
16. Bristol-Myers Squibb announces that the US Food and Drug Administration has extended the review timeline for the ipilimumab biologics license application. http://www.drugs.com/nda/ipilimumab_101102.html (accessed 2010 Dec 1).
17. Dillard T, Yedinak CG, Alumkal J, Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 2010;13: 29-38.
18. Kaehler KC, Egberts F, Lorigan P, Hauschild A. Anti-CTLA-4 therapyrelated autoimmune hypophysitis in a melanoma patient. Melanoma Res 2009;19:333-4.
19. Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTLassociated antigen-4 blockade. Clin Cancer Res 2007;13:6681-8.
20. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002;3:611-8.
21. Chikuma S, Bluestone JA. CTLA-4 and tolerance: the biochemical point of view. Immunol Res 2003;28:241-53.
22. Lee KM, Chuang E, Griffin M, et al. Molecular basis of T cell inactivation by CTLA-4. Science 1998;282:2263-6.
23. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007;110:2614-27.
24. Kwon ED, Hurwitz AA, Foster BA, et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A 1997;94:8099-103.
25. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-6.
26. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006;18:206-13.
27. Cranmer LD, Hersh E. The role of the CTLA4 blockade in the treatment of malignant melanoma. Cancer Invest 2007;25:613-31.
28. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol 2006;90:297-339.
29. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007;7:95-106.
30. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 2008;26:5275-83.
31. Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005; 23:741-50.
32. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003;100: 8372-7.
33. Weber JS, O'Day S, Urba W, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008;26:5950-6.
34. Product information. Yervoy (ipilimumab). Princeton, NJ: Bristol-Myers Squibb, March 2011.
35. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomized, double-blind, multicentre, phase 2, dose ranging study. Lancet Oncol 2010;11:155-64.
36. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92: 205-16.
37. O'Day SJ, Maio M, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010;8:1712-7.
38. Hersh EM, O'Day SJ, Powderly J, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs 2010 (Epub ahead of print).
39. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363: 711-23.
40. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
41. Schwartzentruber DJ, Lawson D, Richards J, et al. A Phase 3 multi-institutional randomized study of immunization with the gp100:209-217 (210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma (abstract). J Clin Oncol 2009;27(suppl):463s.
42. Schartz NEC, Farges C, Madelaine I, et al. Complete regression of a previously untreated melanoma brain metastasis with ipilimumab. Melanoma Res 2010;20:247-50.
43. Dacarbazine and ipilimumab vs dacarbazine with placebo in untreated unresectable stage III or IV melanoma. http://clinicaltrials.gov/ct2/show/NCT00324155?term=ipilimumab&rank= 11 (accessed 17 Sep 2010).
44. Bristol-Myers Squibb. Phase III Study of Investigational Compound Ipilimumab Achieves Primary Endpoint of Improvement in Overall Survival in Previously-Untreated Patients with Metastatic Melanoma. http://www.bms.com/news/press_releases/pages/default.aspx (accessed 2011 Mar 30).
45. Medarex Inc. Medarex reports interim data from ongoing ipilimumab combination Phase 1 studies in prostate cancer at American Association for Cancer Research Meeting. www. medarex.com, 15 Apr 2008 Media Release.
46. Medarex Inc. Medarex and Cell Genesys initiate Phase I clinical trial of MDX-010 in combination with GVAX® prostate cancer vaccine. http://www.medarex.com, 13 Sept 2004 (accessed 1 Dec 2010).
47. Media release. Cell Genesys Inc, Medarex Inc. Cell Genesys and Medarex report follow-up data from a Phase I combination therapy trial with GVAX immunotherapy for prostate cancer and ipilimumab (MDX-010) antibody. www. cellgenesys.com, 04 Jun 2007.
48. Media release. Medarex Inc. Ipilimumab (MDX-010) safety and clinical response data in lymphomas and leukemia presented at the 48th American Society of Hematology Annual Meeting. www. medarex.com, 11 Dec 2006 (accessed 1 Dec 2010).
49. Media release. Bristol-Myers Squibb Company. Controlled Phase 2 Study of ipilimumab shows clinical activity in advanced non-small cell lung cancer. www. bms.com, 22 May 2010 (accessed 1 Dec 2010).
50. Hodi FS, Seiden M, Butler M, et al. Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody blockade in patients previously vaccinated with irradiated, autologous tumor cells engineered to secrete granulocytemacrophage colony stimulating factor (GM-CSF). 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA: 172, Abstract 2536, June 2004, USA.
51. Akhtari M, Waller EK, Jaye DL, et al. Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J Immunother 2009;32:322-4.
52. Gordon IO, Wade T, Chin K, Dickstein J, Gajewski TF. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol Immunother 2009;58:1351-3.
53. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009;15:5591-8.
54. Minor DR, Chin K, Kashani-Sabet M. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. Cancer Biother Radiopharm 2009;24:321-5.
55. Saenger YM, Wolchok JD. The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun 2008;8:1-7.